Diagnostic value of PPARδ and miRNA-17 expression levels in patients with non-small cell lung cancer

作者：Monika Migdalska‐Sęk, B Modrzewska, Jacek Kordiak, Dorota Pastuszak‐Lewandoska, Justyna Kiszałkiewicz, Filip Bielec, Adam Antczak, Ewa Brzeziańska‐Lasota · 发表于：Scientific Reports · 年份：2021 · DOI：10.1038/s41598-021-03312-w · 被引用次数：12 · 研究领域：Peroxisome Proliferator-Activated Receptors、Cholangiocarcinoma and Gallbladder Cancer Studies、Cancer-related molecular mechanisms research

The PPARδ gene codes protein that belongs to the peroxisome proliferator-activated receptor (PPAR) family engaged in a variety of biological processes, including carcinogenesis. Specific biological and clinical roles of PPARδ in non-small cell lung cancer (NSCLC) is not fully explained. The association of PPARα with miRNA regulators (e.g. miRNA-17) has been documented, suggesting the existence of a functional relationship of all PPARs with epigenetic regulation. The aim of the study was to determine the PPARδ and miR-17 expression profiles in NSCLC and to assess their diagnostic value in lung carcinogenesis. PPARδ and miR-17 expressions was assessed by qPCR in NSCLC tissue samples (n = 26) and corresponding macroscopically unchanged lung tissue samples adjacent to the primary lesions served as control (n = 26). PPARδ and miR-17 expression were significantly lower in NSCLC than in the control (p = 0.0001 and p = 0.0178; respectively). A receiver operating characteristic (ROC) curve analysis demonstrated the diagnostic potential in discriminating NSCLC from the control with an area under the curve (AUC) of 0.914 for PPARδ and 0.692 for miR-17. Significant increase in PPARδ expression in the control for current smokers vs. former smokers (p = 0.0200) and increase in miR-17 expression in control tissue adjacent to adenocarcinoma subtype (p = 0.0422) were observed. Overexpression of miR-17 was observed at an early stage of lung carcinogenesis, which may suggest that it acts as a p...